Hoth Therapeutics Secures US Patent for Alzheimer's Treatment, Prepares HT-ALZ Clinical Trials

NEW YORK, Oct. 15, 2024 -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company in the clinical stage, proudly announces the issuance of a U.S. patent for its groundbreaking Alzheimer's treatment, HT-ALZ. This significant patent ensures the company's intellectual property rights over its innovative therapeutic strategy as Hoth gears up for clinical trials.

HT-ALZ marks a significant advancement in Alzheimer's treatment by focusing on the Substance P/Neurokinin-1 Receptor pathway. This pathway is crucial as it plays a major role in neuroinflammation, which is increasingly seen as a key factor in Alzheimer's disease progression. Preclinical studies have yielded encouraging results, showing a reduction in neuroinflammation and considerable improvements in cognitive functions, such as memory and learning.

The patent cements Hoth's position as a leader in developing Alzheimer's therapies, clearing the path for the initiation of human clinical trials. Preparations for these trials are currently in progress, with the aim of bringing this promising treatment to patients as quickly as possible.

Moving Forward
As Hoth Therapeutics completes the formulation phase, the company will prepare for clinical trials to further validate HT-ALZ's effectiveness in humans. These upcoming trials will focus on demonstrating the drug’s safety, tolerability, and its potential to slow or reverse cognitive decline associated with Alzheimer's disease.

Robb Knie, CEO of Hoth Therapeutics, stated, "This patent represents a significant milestone for Hoth as we transition HT-ALZ from laboratory research to clinical development. The preclinical data showing reductions in neuroinflammation and improvements in cognitive function provide great optimism, and we are eager to take the next steps towards delivering a potentially transformative therapy to Alzheimer's patients."

About HT-ALZ
HT-ALZ is a novel approach in Alzheimer's research, focusing on reducing neuroinflammation rather than just targeting amyloid plaques, as many current treatments do. Preclinical data has shown that HT-ALZ effectively reduces reactive astrocytes in the brain, cells that contribute to the inflammatory processes observed in Alzheimer's, thereby improving cognitive outcomes in experimental models.

About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative and impactful treatments aimed at improving patient quality of life. The company is a key player in early-stage pharmaceutical research and development, advancing drugs from laboratory research to pre-clinical and clinical testing. Adopting a patient-centric approach, Hoth collaborates with scientists, clinicians, and key opinion leaders to explore therapies with significant potential to create breakthroughs and diversify treatment options.